Moises Armides Franco-Molina

Dr. Moises Armides Franco-Molina


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HMHéctor Alexander López Muñoz
Héctor Alexander López Muñoz
JLJosé Mauricio López-Romero
José Mauricio López-Romero
MFMoises Armides Franco-Molina
Moises Armides Franco-Molina
AMAlejandro Manzano-Ramirez
Alejandro Manzano-Ramirez
MMMaría Cristina Velasquillo Martínez
María Cristina Velasquillo Martínez
GLGabriel Luna-Barcenas
Gabriel Luna-Barcenas
Herein, we report the synthesis of Au nanoparticles (AuNPs) in chitosan (CTS) solution by chemically reducing HAuCl4. CTS was further functionalized with glycidyl methacrylate (chitosan-g-glycidyl methacrylate/AuNP, CTS-g-GMA/AuNP) to improve the mechanical properties for cellular regeneration requirements of CTS-g-GMA/AuNP. Our nanocomposites promote excellent cellular viability and have a positive effect on cytokine regulation in the inflammatory and anti-inflammatory response of skin cells. After 40 days of nanocomposite exposure to a skin wound, we showed that our films have a greater skin wound healing capacity than a commercial film (TheraForm®), and the presence of the collagen allows better cosmetic ave aspects in skin regeneration in comparison with a nanocomposite with an absence of this protein. Electrical percolation phenomena in such nanocomposites were used as guiding tools for the best nanocomposite performance. Our results suggest that chitosan-based Au nanocomposites show great potential for skin wound repair.

31 January 2026 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
KNKevin Antonio Cárdenas Noriega
Kevin Antonio Cárdenas Noriega
Joel Horacio Elizondo-LuevanoJoel Horacio Elizondo-Luevano
Joel Horacio Elizondo-Luevano
AMAbelardo Chávez Montes
Abelardo Chávez Montes
LRLuis Edgar Rodríguez-Tovar
Luis Edgar Rodríguez-Tovar
MFMoises Armides Franco-Molina
Moises Armides Franco-Molina
UZIEL CASTILLO VELAZQUEZUZIEL CASTILLO VELAZQUEZ
UZIEL CASTILLO VELAZQUEZ
Background: Phytocannabinoids such as cannabidiol (CBD) and cannabigerol (CBG) have received increasing attention in the context of inflammatory and intestinal disorders. However, direct comparisons between their individual and combined effects, as well as the influence of delivery systems, remain limited. Objectives: This study evaluated the biological effects of free and nanoencapsulated CBD and CBG, including a cannabinoid–Eudragit L100 formulation, in an in vitro TNBS-treated intestinal cell model and an in vivo murine model of TNBS-induced colitis. Methods: Cytotoxicity and treatment-associated effects of CBD, CBG, their 1:1 combination, and a nanoencapsulated formulation were assessed in TNBS-exposed Caco-2 cells. In parallel, BALB/c mice with TNBS-induced colitis were evaluated for colonic damage and inflammatory markers. Results: CBD and CBG individually showed dose-dependent effects in Caco-2 cells, while their combined administration produced a greater effect than either compound alone at higher concentrations. The nanoencapsulated formulation preserved cellular metabolic activity following TNBS exposure. In vivo, both free combined and nanoencapsulated cannabinoids were associated with reduced epithelial damage and inflammatory alterations. Conclusions: Nanoencapsulation using Eudragit L100 modulated the biological effects of CBD and CBG in experimental models of TNBS-induced intestinal injury.